Litcius/Paper detail

British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease

David L. Smith, Ingrid Du Rand, C. Addy, Timothy Collyns, Simon P. Hart, Philip Mitchelmore, Najib M. Rahman, Ravijyot Saggu

2020Thorax64 citationsDOIOpen Access PDF

Abstract

Table 1 Summary of outcome measures population intervention Control outcomes Adults with asthma Long-term, lowdose macrolides Placebo Quality-of-life measures Symptom improvement/symptom score Exacerbation rates Hospital admission rate Disease progression and changes in lung function tests Mortality Exercise capacity/tolerance Sputum volume/colour/character and microbiological resistance/dysbiosis Drug monitoring/side effects/toxicity Adults with bronchiectasis Adults with COPD Adults with bronchiolitis obliterans Adults with chronic cough Adults with organising pneumonia Adults with diffuse panbronchiolitis

Topics & Concepts

MedicineBronchiolitis obliteransBronchiectasisPneumoniaExacerbationAsthmaQuality of life (healthcare)PopulationPulmonary function testingCOPDIntensive care medicineInternal medicinePhysical therapyLungNursingEnvironmental healthLung transplantationRespiratory and Cough-Related ResearchChronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseases
British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease | Litcius